These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32814264)

  • 1. Staging of depressive disorders: Relevance of resistance to treatment and residual symptoms.
    Reneses B; Aguera-Ortiz L; Sevilla-Llewellyn-Jones J; Carrillo A; Argudo I; Regatero MJ; López-Micó C; Fuentes M; Palomo T
    J Psychiatr Res; 2020 Oct; 129():234-240. PubMed ID: 32814264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardisation framework for the Maudsley staging method for treatment resistance in depression.
    Fekadu A; Donocik JG; Cleare AJ
    BMC Psychiatry; 2018 Apr; 18(1):100. PubMed ID: 29642877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of the Maudsley Staging Method in Predicting Treatment-Resistant Depression Outcome Using the Netherlands Study of Depression and Anxiety.
    van Belkum SM; Geugies H; Lysen TS; Cleare AJ; Peeters FPML; Penninx BWJH; Schoevers RA; Ruhe HG
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29370485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of remission in 208 drug-resistant depressive patients treated with electroconvulsive therapy.
    Medda P; Mauri M; Toni C; Mariani MG; Rizzato S; Miniati M; De Simone L; Perugi G
    J ECT; 2014 Dec; 30(4):292-7. PubMed ID: 24625706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Maudsley Staging Method as predictor of electroconvulsive therapy effectiveness in depression.
    van Diermen L; Hebbrecht K; Schrijvers D; Sabbe BCG; Fransen E; Birkenhäger TK
    Acta Psychiatr Scand; 2018 Dec; 138(6):605-614. PubMed ID: 30270433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management strategies for major depressive episodes as a function of initial response to an SSRI or SNRI antidepressant: results of the ORACLE survey].
    Spadone C; Sylvestre M; Chiarelli P; Richard-Berthe C
    Encephale; 2005; 31(6 Pt 1):698-704. PubMed ID: 16462689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis.
    Guico-Pabia CJ; Fayyad RS; Soares CN
    Int Clin Psychopharmacol; 2012 Jan; 27(1):1-7. PubMed ID: 21971533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.
    Connolly KR; Helmer A; Cristancho MA; Cristancho P; O'Reardon JP
    J Clin Psychiatry; 2012 Apr; 73(4):e567-73. PubMed ID: 22579164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report.
    Braund TA; Palmer DM; Williams LM; Harris AW
    Aust N Z J Psychiatry; 2019 Aug; 53(8):782-793. PubMed ID: 30880405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms.
    Fekadu A; Wooderson SC; Markopoulou K; Cleare AJ
    J Clin Psychiatry; 2009 Jul; 70(7):952-7. PubMed ID: 19457299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptom differences between depressed outpatients who are in remission according to the Hamilton Depression Rating Scale who do and do not consider themselves to be in remission.
    Zimmerman M; Martinez J; Attiullah N; Friedman M; Toba C; Boerescu DA
    J Affect Disord; 2012 Dec; 142(1-3):77-81. PubMed ID: 22980402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for bipolar disorder in a Spanish sample of outpatients with current major depressive episode.
    Tafalla M; Sanchez-Moreno J; Diez T; Vieta E
    J Affect Disord; 2009 Apr; 114(1-3):299-304. PubMed ID: 18701169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of St John's wort in major depression: a randomized controlled trial.
    Shelton RC; Keller MB; Gelenberg A; Dunner DL; Hirschfeld R; Thase ME; Russell J; Lydiard RB; Crits-Cristoph P; Gallop R; Todd L; Hellerstein D; Goodnick P; Keitner G; Stahl SM; Halbreich U
    JAMA; 2001 Apr; 285(15):1978-86. PubMed ID: 11308434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.
    Dunlop BW; Li T; Kornstein SG; Friedman ES; Rothschild AJ; Pedersen R; Ninan P; Keller M; Trivedi MH
    J Psychiatr Res; 2011 Jan; 45(1):96-103. PubMed ID: 20537348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review.
    de Zwart PL; Jeronimus BF; de Jonge P
    Epidemiol Psychiatr Sci; 2019 Oct; 28(5):544-562. PubMed ID: 29769159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
    J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.